SERVIER PHARMA LLC
BiotechSERVIER PHARMA LLC is a biotechnology company focused on Oncology, Cardiovascular.
FDA Novel Drug Designations
(2018)See 1 novel approval →
SERVIER PHARMA LLC's Key Drugs
SERVIER PHARMA LLC's core commercial portfolio centers on ASPARLAS, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
SERVIER PHARMA LLC's Recent FDA Approvals
New NDA/BLA approvals for SERVIER PHARMA LLC over the last two years — novel drugs only, excluding generics and label supplements.
SERVIER PHARMA LLC's Therapeutic Areas
SERVIER PHARMA LLC's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SERVIER PHARMA LLC's Top Competitors
SERVIER PHARMA LLC's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SERVIER PHARMA LLC Pipeline Snapshot
SERVIER PHARMA LLC has 2 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ASPARLAS leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/14 completed
- • Speed: 36 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2018-12-20
- Latest
- 2023-11-29
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges